CoChat

Current Alzheimer's disease clinical trials: Methods and placebo outcomes

Open access
Schneider, Lon S., Sano, Mary · 2009 · Alzheimer's & Dementia
Cited by 137

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: Eighteen‐month‐long randomized, placebo‐controlled clinical trials are common for phase II and phase III drug development for Alzheimer's disease (AD). Yet, no 18‐month trial has shown statistically significant outcomes favoring the test drug. We examined characteristics and underlying assumptions of these trials by assessing the placebo groups. Methods: We searched the clinicaltrials.gov registry for randomized, placebo‐controlled clinical trials for AD of at least 18‐month duration and extracted demographic, clinical, and trials characteristics, and change in main outcomes from the placebo groups. We obtained additional information from presentations, abstracts, publications, and sponsors. Results: Of 23 trials identified, 11 were completed and had baseline data available; nine had follow‐up data available; 17 were phase III. General inclusion criteria were very similar except that minimum Mini‐Mental State Examination (MMSE) scores varied from 12 to 20. Sample sizes ranged from 402 to 1,684 for phase III trials and 80 to 400 for phase II. Cholinesterase inhibitor use was from 53% to 100%, and memantine use was from 13.5% to 78%. The AD Assessment Scale‐cognitive (ADAS‐cog) was the co‐primary outcome in all trials; and activities of daily living, global severity, or global change ratings were the other co‐primaries. APOE ɛ4 genotype carriers ranged from 58% to 67%; mean baseline ADAS‐cog was 17.8 to 24.2. ADAS‐cog worsening in the placebo groups during 18 months ranged from 4.34 to 9.10, with standard deviations from 8.17 to 9.39, increasing during 18 months. Conclusions: Inclusion criteria are essentially similar to earlier 6‐month and 12‐month trials in which cholinesterase inhibitors were not allowed, as were mean ADAS‐cog rates of change. Yet increasing variability and relatively little change overall in the ADAS‐cog placebo groups, eg, about 25% of patients do not worsen by more than 1 point, might make it more unlikely than previously assumed that a modestly effective drug can be reliably recognized, especially when the drug might work only to attenuate decline in function and not to improve function. These observations would be strengthened by pooling individual trials data, and pharmaceutical sponsors should participate in such efforts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2009.07.038

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 137

Metadata

Authors
Schneider, L. S., & Sano, M.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2009-09
Volume
5
Issue
5
Pages
388-397
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2039140744
Cited by
137
References
2
FWCI
10.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Current Alzheimer's disease clinical trials: Methods and placebo outcomes. https://app.cochat.ai/papers/10.1016/j.jalz.2009.07.038
The paper
Schneider, L. S., & Sano, M. (2009). Current Alzheimer's disease clinical trials: Methods and placebo outcomes. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2009.07.038

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.